On Friday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) opened lower -1.63% from the last session, before settling in for the closing price of $7.96. Price fluctuations for IOVA have ranged from $6.38 to $18.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 33.29% at the time writing. With a float of $247.05 million, this company’s outstanding shares have now reached $304.62 million.
The extent of productivity of a business whose workforce counts for 557 workers is very important to gauge. In terms of profitability, gross margin is -13.57%, operating margin of -473.22%, and the pretax margin is -458.02%.
Iovance Biotherapeutics Inc (IOVA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iovance Biotherapeutics Inc is 18.94%, while institutional ownership is 68.47%. The most recent insider transaction that took place on Nov 12 ’24, was worth 503,000. In this transaction Director of this company sold 50,000 shares at a rate of $10.06, taking the stock ownership to the 7,500 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Director proposed sale 50,000 for $10.06, making the entire transaction worth $503,104.
Iovance Biotherapeutics Inc (IOVA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 33.29% per share during the next fiscal year.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Check out the current performance indicators for Iovance Biotherapeutics Inc (IOVA). In the past quarter, the stock posted a quick ratio of 3.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.50, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Iovance Biotherapeutics Inc (IOVA)
The latest stats from [Iovance Biotherapeutics Inc, IOVA] show that its last 5-days average volume of 5.05 million was inferior to 7.19 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 9.11%. Additionally, its Average True Range was 0.52.
During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 13.35%, which indicates a significant increase from 6.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.86% in the past 14 days, which was lower than the 76.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.65, while its 200-day Moving Average is $10.48. Now, the first resistance to watch is $8.01. This is followed by the second major resistance level at $8.19. The third major resistance level sits at $8.35. If the price goes on to break the first support level at $7.67, it is likely to go to the next support level at $7.51. The third support level lies at $7.33 if the price breaches the second support level.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats
There are currently 304,781K shares outstanding in the company with a market cap of 2.35 billion. Presently, the company’s annual sales total 1,190 K according to its annual income of -444,040 K. Last quarter, the company’s sales amounted to 58,560 K and its income totaled -83,540 K.
